Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed / Refractory T-cell Lymphoma

Lymphoma

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R / R T-cell lymphoma.
Lymphoma
I/II
Reddy, Nishitha
NCT03770000
VICCPCL1937

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: